The Playground

    Designing the perfect vaccine to COVID is analogous to designing the perfect LENR - based fusion reactor. ALL AVENUES OF RESEARCH MUST be PURSUED. My advice is to order your own personal supply of ZIVERDO from INDIA to supplement any (including vaccination) other therapies I have outlined in our ANT-BAT cocktail of drugs and vitamins. Just to keep safe and healthy whatever age or co-morbidities you have. :) :) :)

    Quote from Mark U

    My point is, that decrease in effectiveness against different strains pales in comparison to the vaccine's inherent decline in effectiveness over time irregardless of the strain.

    Well we can agree that both vaccines and natural immunity for COVID wane over time.


    The data shows efficacy waning a lot over 6 months. (After 6 months it is similar to that of Flu jabs, except that for Flu jabs).


    It does not show effectiveness against severe infection or death waning in the same way. There are good reasons for that.


    As for whether vaccines will work as well against omicron - we will have to wait and see.


    New USA study confirms VE wanes to ~50% after 5m, but VE vs. hospitalization remains strong at >90%
    A paper published October 4, 2021 in The Lancet based on >3.4m USA patients found Pfizer vaccine effectiveness (VE) vs. infection decreased from 88% 1m after…
    www.covid-datascience.com

    Quote from Zephir_AWT

    Do you really believe that immune system trained to single spike protein from whole virus will work as precisely and reliably like immune system trained to all other 29 proteins at the same moment? The white immune cells trained to spike protein only would behave like white cops, who just learned from criminal statistics that blacks are bad because of their colour: such a cops will indeed attack many innocent blacks and vice versa, they will leave white criminals unpunished. Simply because they learned to spot and recognize criminals by single aspect of their existence.


    Another problem of immunity trained to single protein (which m-RNA vaccines do) is, once this protein mutates, then whole the vaccination becomes toothless as we can already observe with delta etc variants of coronavirus.

    I'd agree those are problems, but not that they make the choice (for mRNA or subunit vaccines) to use spike proteins a bad one.


    For a start the spike protein is better conserved because it's needed function depends on precise shape. Targetting the non-spike proteins in vaccines or natural immunity would be easier for the virus to evade.

    Secondly we have vaccines designed for original COVID that work well against delta which emerged after 1.5 years. That is pretty good.


    But don't worry - there are many 2nd gen vaccine in development. It is a toss up whether to handle omicron we will rely on current vaccines + them, or whether we will go for 100 day development new mRNA vaccines.


    The big advantage of mRNA is that it can be grown at scale much more quickly (and cheaply) than other vaccines. We are just very lucky that delta did not emerge 10 years ago.

    77% vaccination + Japanese people being very careful at mask-wearing and social distancing seems enough to me. UK has 68% + effectively no mask-wearing or social distancing, and delta infection rate has been kept constant over the last 4 months. Also Japan's vaccination campaign is much more recent than the UK's, and so vaccinations will be more efficacious (at reducing transmission).


    To be quantitative: 77% vs 68% is 23% unvaccinated vs 32%. If we assume that R is dominated by the unvaccinated (true for a recently vaccinated country) they have R value 1.4 X smaller than the UK from vaccination. Another factor (1.3X perhaps). I am very unsure about how much social distancing decreases R in a mostly vaccinated country - it is certainly significant and could be in range 1.2 - 2. Even at the lower end that seems easily enough to have R << 1.


    I don't really understand the "mutate to extinction" argument. As soon as any mutation reduced R it would be out-competed by the non-mutated strain.


    THH

    Quote from THHuxleynew

    I don't really understand the "mutate to extinction" argument. As soon as any mutation reduced R it would be out-competed by the non-mutated strain.

    Don't confuse infectivity with virulence. A virus mutation that is highly infectious but also relatively benign will not be outcompeted, or even detected in many cases. There is good reason to believe that our bodies are already a host for many such strains.


    My initial training was as a bacteriologist, and my mentor told me (speaking of bacteria) "Some pathogenic bacteria create empires with deadly effect and then vanish in the night, others are more stealthy and find quiet corners to live in, with just the occasional effort at dominance."


    I think the same can be said of viruses.

    Quote from Wyttenbach

    What is unluckily the case in almost all western countries. Sweden did a great job, Switzerland did less but still much more than most others. Free (of mask no 3G) skiing over Christmas new year!


    To many Nazi doctors e.g. in Germany now block the media!

    Falling back into wellknown pattern? Thought this was gone now…


    Kind of a deja-vu today unfortunately in German news. ☹️


    +++ 12:53 Buchenwald Concentration Camp Memorial: Hate emails and insults after the introduction of the 2G rule +++


    After restricting access, the Buchenwald concentration camp memorial only receives hate emails for vaccinated and recovered people. Employees would also have to endure drastic telephone insults, according to a communication from the memorial on its website. The aggressiveness that strikes us testifies to a frightening brutalization, explains Jens-Christian Wagner, director of the Buchenwald and Mittelbau-Dora Memorials Foundation. However, the most disgusting is the equating of corona protection measures with Nazi crimes. For example, unvaccinated people would be considered "new Jews" and memorial employees as "Nazis, fascists and new Dr. Mengeles" insulted.

    Quote from Alan Smith

    Don't confuse infectivity with virulence. A virus mutation that is highly infectious but also relatively benign will not be outcompeted, or even detected in many cases. There is good reason to believe that our bodies are already a host for many such strains.


    My initial training was as a bacteriologist, and my mentor told me (speaking of bacteria) "Some pathogenic bacteria create empires with deadly effect and then vanish in the night, others are more stealthy and find quiet corners to live in, with just the occasional effort at dominance."


    I think the same can be said of viruses.

    2009/2010 H1N1 is a good example

    Take a look at this paper from early on in the pandemic. I think the Japanese researchers are on to something. Omicrom also carries mutations at nsp14


    Mutations of SARS-CoV-2 nsp14 exhibitstrong association with increasedgenome-wide mutation load


    (PDF) Mutations of SARS-CoV-2 nsp14 exhibit strong association with increased genome-wide mutation load
    PDF | SARS-CoV-2 is a betacoronavirus responsible for COVID-19, a pandemic with global impact that first emerged in late 2019. Since then, the viral... | Find,…
    www.researchgate.net

    Quote from THHuxleynew

    It does not show effectiveness against severe infection or death waning in the same way.

    Silly statement. Here (CH) the last two weeks > 50% deaths with double vax. So we too are now in the pandemic of the vaccinated. The vaxx rate is around 67% now. So now average vaccine protection from death is still 2x. But within 5 weeks it will be 20%....

    Our clowns here still try to promotes FM/R/B FUD on all levels e.g. by citing outdated studies.


    In a pandemic only actual data counts. We today exactly know why the Pfizer study data is a total fake. So fake news usually focus on a narrow data set and narrow time frame to undermine a fake view of reality.


    Fact: The RNA gene therapy (vaccines..) never did prevent infection from SARS CoV-19. This only looks like so if you test in a low load situation and discount all early infection in the Pfizer case.


    Vaccine passports are the new "J" stamp as they are a fascist measure that just is founded on fake facts like once seen in Germany 1932. The vaccinated to not protect anybody!!!!

    Vaccinated people get more often CoV-19 than unvaccinated. See actual UK data. But recovered can no longer spread virus. So the contrary is true: Vaccinated endanger far more people than unvaccinated!


    In reality only tested and recovered should get a freedom pass. But for fascists freedom is defined by self defined fake facts. It looks like some J friends still believe they have a monopole to be a victim...

    IVERMECTIN = "ziverdo kit" saves India


    #IndiaFightsCorona COVID-19
    www.mygov.in


    But the small vaccine terror state completely distorts the reality. They did dig out 500 more hidden deaths and thus today 90% of all India's deaths come from the small super vaccine state doing no Ivermectin treatment.


    The rest of India is compared to the rest of world free of CoV-19. Uttar Pradesh since 4 months has less than 10 cases/day in average. This for 235 mio people and a low vaccination rate.


    The western fascist terror governments worst AUS,CAN,FR,DE could learn a lot from India. But if you can make 1000'000'000'000 $$ instead of 1'000'000'000 there is no way out.


    So we currently see the biggest extortion of western countries tax payers by the FM/R/J/B world wide mafia.


    For me this now has a much bigger dimension than WWII, as these people are willing to kill everybody that is not willing to pay ransom money...

    Quote from Alan Smith

    Don't confuse infectivity with virulence. A virus mutation that is highly infectious but also relatively benign will not be outcompeted, or even detected in many cases. There is good reason to believe that our bodies are already a host for many such strains.

    The current PCR tests are relatively non-specific - they detect all known variants

    Random sample whole population testing shows number of infected

    ONS survey in UK (for example) combines this with measurement of symptoms

    We know that (in UK) asymptomatic COVID is a signiifcant fraction of total, and we track it


    So unless you suggest a variant very far from existing strains - even farther than omicron - (but chances of this happening by chance are low) we will detect and sequence it.

    If it is detected - we have a good estimate for the number of such silent infections.


    COVID is more heavily tested and sequenced than any otehr virus in history.


    I agree that a benign infectious variant of COVID is what we would all like. Perhaps it will happen. But, unless omicron really is benign, as a few (mainly those in SA) hope, we have not seen it yet.


    I can't see a benign variant going undetected given that most countries to random sample population testing, and any such variant would rapidly spread between countries.

    I've often thought that nano Fission and nano Fusion and ZPE might all be happening to some degree in different types of LENR Electric CMNS reactors. The Advanced Energy Conversion project at NASA GRC and the works of GEC lend weight to this thought... perhaps?



    A Review of Previous Research in Direct Energy Conversion Fission Reactors

    From the earliest days of power reactor development, direct energy conversion was an obvious choice to produce high efficiency electric power generation. Directly capturing the energy of the fission fragments produced during nuclear fission avoids the intermediate conversion to thermal energy and the efficiency limitations of classical thermodynamics. Efficiencies of more than 80% are possible, independent of operational temperature. Direct energy conversion fission reactors would possess a number of unique characteristics that would make them very attractive for commercial power generation. These reactors would be modular in design with integral power conversion and operate at low pressures and temperatures. They would operate at high efficiency and produce power well suited for long distance transmission. They would feature large safety margins and passively safe design. Ideally suited to production by advanced manufacturing techniques, direct energy conversion fission reactors could be produced more economically than conventional reactor designs. The history of direct energy conversion can be considered as dating back to 1913 when Moseleyl demonstrated that charged particle emission could be used to buildup a voltage. Soon after the successful operation of a nuclear reactor, E.P. Wigner suggested the use of fission fragments for direct energy conversion. Over a decade after Wigner's suggestion, the first theoretical treatment of the conversion of fission fragment kinetic energy into electrical potential appeared in the literature. Over the ten years that followed, a number of researchers investigated various aspects of fission fragment direct energy conversion. Experiments were performed that validated the basic physics of the concept, but a variety of technical challenges limited the efficiencies that were achieved. Most research in direct energy conversion ceased in the US by the late 1960s. Sporadic interest in the concept appears in the literature until this day, but there have been no recent significant programs to develop the technology.

    INSERM-based Researchers’ Data Model Suggests ADE a Possibility with COVID-19 Delta Variant & Current Vaccines


    INSERM-based Researchers’ Data Model Suggests ADE a Possibility with COVID-19 Delta Variant & Current Vaccines
    A trio of researchers affiliated with the prominent national research center of France—INSERM as well as Aix Marseille University suggest the possible
    trialsitenews.com


    A trio of researchers affiliated with the prominent national research center of France—INSERM as well as Aix Marseille University suggest the possible risks for antibody-dependent enhancement (ADE) in association with mass COVID-19 vaccination schemes since the onset of the Delta variant. ADE represents a safety concern associated with vaccination strategies. Previous research investigated ADE with SARS-CoV-2 focusing on the wild type or original strain of SARS-CoV-2 called Wuhan/D614G. However, as the delta variant now represents the majority of strains the study team investigated the interaction of infection-enhancing antibodies directed against the N-terminal domain (NTD) of the SARS-CoV-2 spike protein. Employing molecular modeling methods, the INSERM-based team demonstrates that enhancing antibodies show a higher attraction for Delta variants over the original Wuhan/D614 N-terminal domain (NTD) of the SARS-CoV-2 spike protein. The authors propose that based the observations from their modeling enhancing antibodies reinforce the binding of the spike trimer to the host cell membrane via the clamping of the NTD to lipid raft microdomains. Do these stabilizing mechanisms expedite the conformational change that stimulates the demasking of the receptor binding domain? The study authors propose that based on their modeling in the case of the original Wuhan strain of SARS-CoV-2 “the balance between neutralizing and facilitating antibodies in vaccinated individuals is in favor of neuralization.” But with Delta the neutralizing antibodies demonstrate less “affinity for the spike protein, whereas facilitating antibodies display a strikingly increased affinity.” This implies that the masses of population receiving COVID-19 vaccines based on the original Wuhan strain spike sequence (mRNA or viral vectors) face potential risk of ADE. Consequently, the authors posit that “Second generation vaccines with spike protein formulations lacking structurally-conserved ADE-related epitopes should be considered” moving forward. Other prominent figures such as Dr. Paul Offit contend that there is no evidence that the four types of coronaviruses associate with any ADE.


    Back in August the work of Nouara Yahi, Henri Chahinian and Jacques Fantini, all affiliated with INSERM or Aix Marseille University, was published as a letter in the Journal of Infection. Titled “Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D6114G strain and Delta variants. A potential risk for mass vaccination?” the authors put forth a disturbing and politically unpopular proposition, but one that nonetheless must be disseminated and better understood.


    What is ADE?

    The term Antibody dependent enhancement is often mentioned but few understand what this really means. Antibodies come from B cells, those cells created in bone marrow and typically spend their life in the lymph nodes. These antibodies do a number of things for us including binding to either A) toxin B) bacteria or C) viruses.


    ADE can be thought of as an alternative key that a virus such as SARS-CoV-2 uses to enter the human immune cells. With spike proteins the first and primary key involves the virus’ ability to penetrate one or two kinds of cells, such as lung cells or neurons. When antibodies bind to a virus in a non-neutralizing way they penetrate macrophages, a type of immune cell. If an antibody binds in a non-positive, non-neutralizing manner the virus may be given the opportunity to enter immune cells (macrophages) thus advancing the virus’ mission. An example of ADE would be a topical virus known as Dengue virus. ADE occurs during Dengue virus infections and also has occurred during RSV vaccine clinical trials. To date there is no commonly accepted evidence that ADE is associated with mass COVID-19 vaccination.


    Why are COVID-19 Vaccines unlikely to include ADE?

    Dr. Paull Offit, Children’s Hospital of Philadelphia, Vaccine Education Center discusses the highly unlikely prospect of ADE in the context of COVID-19 vaccines. The prominent American academic medical researcher offered his point of view during a YouTube video published back in February, before the Delta variant of concern surfaced in the world.


    Seen with Dengue virus, Offit notes the various types of dengue virus—pointing out that if someone is infected with one type and then recovers, and then infected with a second type, the disease is much worse than the first time.


    Offit educates that there was preliminary worry about ADE with COVID-19 because some evidence with animal studies associated with the first coronavirus (SARS-CoV-1). But in association with SARS-CoV-2 Offit assures the possibility of ADE is highly unlikely.


    Explaining that there are four types of human coronaviruses, Offit shared that if a person is infected with one type of coronavirus and thereafter infected with a second type of coronavirus, he pointed out You don’t have that phenomenon of so-called antibody-dependent enhancement; that is where the second infection is far worse than the first viral infection.


    Offit also mentions research done in the 1990s involving coronaviruses not evidencing any ADE. Moreover, Offit pointed to specific animal studies where lab animals infected with SARS-CoV-2 virus were then exposed to SARS-CoV-2 again. While he didn’t cite the actual study, Offit did articulate that the researchers found no evidence of ADE. Also, Dr. Offit points out that animals administered with the COVID-19 vaccine and then exposed to SARS-CoV-2 infection don’t develop ADE.


    Lastly Offit claims that if people who are infected with SARS-CoV-2 are given antibodies, so-called convalescent plasma directed against the pathogen, they too don’t develop ADE. Thus Dr. Offit declares that while concerns for ADE that were associated with SARS-CoV-1 were understandable he argues in the video that we now have five separate pieces of evidence suggesting that ADE is not a risk with this virus nor with the vaccines developed to protect against this virus.


    What do the INSERM-based researchers claim?

    Back to the trio of scientists from INSERM. These authors share that all the current COVID-19 vaccines on the market in the West, whether mRNA or viral vectors, are based on the original Wuhan spike sequence. They argue that ADE is not a concern when “neutralizing antibodies overwhelm facilitating antibodies.”


    But what happens with the emergence of new SARS-CoV-2 variants? Can they tip the scales in favor of infection enhancement? According to the study authors’ data model the unfortunate prospect that Delta in fact disrupts this previous balance, thus again tipping the scales in favor of infection.


    After cranking through data models associated with two mutations, the authors proposed that in fact ADE may be a risk for people that were vaccinated with vaccine products developed based on the original Wuhan strain spike sequence then subsequently exposed to the Delta variant.


    The authors point out that “the ability of SARS-CoV-2 antibodies to mediate infection enhancement in vivo (in living organism) has never been formally demonstrated.” They do point out that based on vaccination records thus far “The results obtained so far have been rather reassuring.” But TrialSite does remind the reader of the inordinate spike in adverse events and deaths in the Center for Disease Control and Prevention (CDC) VAERS safety registry. Of course, one big challenge has been proving that these adverse events are associated with the vaccine.


    The French authors are not aware of any specific formal assessments of ADE associated with the Delta variant. Noting that “Delta variants are especially well recognized by infection enhancing antibodies targeting the NTD, the possibility of ADE should be further investigated as it may represent a potential risk for mass vaccination during the current Delta variant pandemic.”


    If ADE is truly a possibility the authors emphasize the importance that government research agencies and vaccine producers consider the development of “second generation vaccines with spike protein formulations lacking structurally-conserved ADE-related epitopes.”


    Lead Research/Investigator

    Nouara Yahi


    Henri Chahinian


    Jacques Fantini, Aix-Marseille Université


    DEFINE_ME

    Retrospective Statistical Analysis Indicates Ivermectin a COVID-19 Stopper in Africa


    Retrospective Statistical Analysis Indicates Ivermectin a COVID-19 Stopper in Africa
    Africa stands out in the world for its relatively mild effect from COVID-19. Theories as to why this is the case are multiple running the gamut from
    trialsitenews.com



    Africa stands out in the world for its relatively mild effect from COVID-19. Theories as to why this is the case are multiple running the gamut from underreporting and lack of testing to youthful population and genetic predisposition and even the wide use of ivermectin in numerous countries. Thus far scientists haven’t been able to explain the reason for the continent’s overall low number of COVID-19 cases. Ivermectin is used by dozens of countries in the African continent as an intervention for onchocerciasis. With 67 studies now formally investigating ivermectin as a COVID-19 treatment the prospect of investigating the correlation of low African COVID-19 numbers prompted Japanese researchers to look into this most intriguing of explanations. Hisaya Tanioka, MD, PhD and radiologist and Sayaka Tanioka, both with the Tanioka Clinic in the Bunkyo-Ku district of Tokyo along with Kimitaka Kaga with the National Institute of Sensory Organs, part of the National Hospital Organization, Tokyo Medical Center designed a retrospective statistical analysis study to investigate the impact of ivermectin against COVID-19 with a specific focus on comparing 31 African nations referred to as “onchocerciasis-endemic” all of which use ivermectin as a community-directed treatment and 22 non-endemic African nations. The trio found that in fact COVID-19 illness and death rates are markedly lower in the onchocerciasis endemic countries than the non-endemic ones. Based on the analysis the authors conclude that ivermectin is more than likely the reason that the populations in these African nations experience less severe problems with COVID-19.


    Background

    Programs such as Mectizan were organized to eradicate disease such as the tropical parasite-based disease onchocerciasis, also known as river blindness. African nations that are part of these programs use community-directed treatment with ivermectin (CDTI) as a core strategy to eliminate the parasitic diseases. What are the CDTI countries—that is where over 99% of the onchocerciasis infections are located? The Sub-Saharan nations include Angola, Benin, Burkina Faso, Burundi, Cameroon, Central Africa, Chad, Republic of Congo, Cote d’Ivoire, Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Malawi, Mali, Mozambique, Niger Nigeria, Rwanda, Senegal, Sierra Leone, South Sudan, Sudan, Togo, Uganda, Tanzania


    The community-directed treatment strategy has successfully evolved in these aforementioned nations as a means to overcome challenged, and under-resourced health systems—leading to positive outcomes at low cost.


    Study Hypothesis

    As documented in the preprint manuscript, the Japanese authors posit that “if ivermectin has an antiviral effect on SARS-CoV-2, the morbidity, mortality, recovery, and fatality rates caused by COVID-19 would be reduced in the CDTI countries compared to non-endemic untreated ones. Put another way, do ivermectin-based interventions for onchocerciasis positively impact morbidity, mortality, recovery rate and fatality rate caused by COVID-19.



    The Analysis

    Based on the aforementioned hypothesis, the authors performed epidemiological analysis comparing the two groups—that is the endemic CDTI vs. non-endemic, untreated nations as a means to validate the ivermectin intervention on COVID-19.


    Leveraging World Health Organization (WHO) Africa statistics, the study authors also accessed COVID-19 data from the WHO coronavirus disease Dashboard starting January 15,2021 as well as the COVID-19 Situation update for the WHO African region. The study team calculated morbidity, mortality, recovery rate, and fatality rate caused by SARS-CoV-2.


    Thereafter the Japanese investigators performed statistical analysis using standard measures such as mean, standard deviations, as well as comparative data via the Welch-test defining a two-sided P value <0.05 as a significant threshold.


    The results of this analysis can be viewed in the table below:



    The Results

    The trio of Japanese researchers found that in fact the CDTI countries’ population experience significantly less morbidity and mortality than the non-CDTI countries. Of note population, recovery rate and fatality rate were not statistically significant however the average life expectancy was high in the non-ivermectin group.


    Conclusion

    The researchers concluded that based on this particular statistical analysis, those countries’ populations involved with the community -directed treatment with ivermectin (CDTI) overall fare better than the non-endemic country group. More specifically, the populations in the CDTI African countries experience a reduction in mortality, an acceleration of patient recovery and lower death rates.


    The investigators found in this African-focused epidemiological probe that “the morbidity and mortality in the onchocerciasis-endemic countries (Ivermectin group) are statistically lesser than those in the non-endemic ones (non-Ivermectin group).”


    Noted by the study authors, however, mortality associated with COVID-19 is also dependent on testing and these CDTI countries tend to have weak medical systems that lack effective testing regimens. They note because of poverty, weak health systems and relate factors that observed incidence of lower COVID-19 rates in the CDTI countries however mortality is unrelated to number of tests. The mortality is lower in the CDTI group vs. the non-endemic countries.


    Limitations

    This retrospective statistical analysis study hasn’t been peer reviewed thus it should not be cited authoritatively as medical evidence. It does represent an under-covered body of work deserving of more scrutiny.


    Generally observational studies such as this represent a lower standard of evidence than experimental studies, often more prone to bias and confounding factors. They cannot be used to demonstrate causality with conclusive confidence.


    Lead Research/Investigator

    Hisaya Tanioka, MD, PhD Tanioka Clinic


    Sayaka Tanioka, Tanioka Clinic


    Kimitaka Kaga, National Institute of Sensory Organs, part of the National Hospital Organization, Tokyo Medical Center


    Call to Action: The study authors declare “This analytical study will suggest that early treatment with ivermectin may accelerate recovery and prevent worsening of symptoms in patients with mild disease. These findings can be efficiently translated into therapies for SARS-CoV-2 (COVID-19).” TrialSite recommends to interested investigators to further vet this research


    Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?

    Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?
    Background Scientists have so far been unable to determine the reason for the low number of COVID-19 cases in Africa. Objective To evaluate the impact of…
    www.medrxiv.org


    Abstract

    Background Scientists have so far been unable to determine the reason for the low number of COVID-19 cases in Africa.


    Objective To evaluate the impact of ivermectin interventions for onchocerciasis on the morbidity, mortality, recovery, and fatality rates caused by COVID-19.


    Method A retrospective statistical analysis study of the impact of ivermectin against COVID-19 between the 31 onchocerciasis-endemic countries using the community-directed treatment with ivermectin (CDTI) and the non-endemic 22 countries in Africa. The morbidity, mortality, recovery rate, and fatality rate caused by COVID-19 were calculated from the WHO situation report in Africa. We investigated the onchocerciasis endemic 31 countries and the non-endemic 22 countries. Statistical comparisons used by the Welch test of them in the two groups were made.


    Results The morbidity and mortality were statistically significantly less in the 31 countries using CDTI. The recovery and fatality rates were not statistically significant difference. The average life expectancy was statistically significantly higher in the non-endemic countries.


    Conclusions The morbidity and mortality in the onchocerciasis endemic countries are lesser than those in the non-endemic ones. The community-directed onchocerciasis treatment with ivermectin is the most reasonable explanation for the decrease in morbidity and fatality rate in Africa. In areas where ivermectin is distributed to and used by the entire population, it leads to a significant reduction in mortality

    Quote from THHuxleynew

    I can't see a benign variant going undetected given that most countries to random sample population testing, and any such variant would rapidly spread between countries.

    I would just point out that the human virome is estimated to consist of up to 380 trillion viral particles. Also look up the term 'commensal' if you don't already know it. Further reading...


    The human virome: assembly, composition and host interactions - Nature Reviews Microbiology
    The human body hosts vast numbers of different viruses, collectively termed the virome. In this Review, Liang and Bushman provide an overview of research on…
    www.nature.com


    Note that only 10,462 had been fully sequenced at the time of writing.

    Quote from Fm1

    Why are COVID-19 Vaccines unlikely to include ADE?

    First we so far have no vaccines only gene therapies that mimic a single vaccine effect. Second why, today,do vaccinated up to 5x more often get COV-19 than the unvaccinated ?? UK vaccine report weeks 43..46...


    I would say the virus smells the vaccine! ...

Subscribe to our newsletter

It's sent once a month, you can unsubscribe at anytime!

View archive of previous newsletters

* indicates required

Your email address will be used to send you email newsletters only. See our Privacy Policy for more information.

Our Partners

Supporting researchers for over 20 years
Want to Advertise or Sponsor LENR Forum?
CLICK HERE to contact us.